Month: March 2017
Population Pharmacokinetics (PK) of Rucaparib (CO-338) in Patients with Advanced Ovarian Cancer (AOC) or Other Solid Tumors
Application of Physiologically-based Pharmacokinetic (PBPK) Modeling to Predict Ondansetron Pharmacokinetics in Children
Predicting Drug Exposure During Pregnancy Using PBPK Models
This webinar described how the Simcyp pregnancy-PBPK model was used to predict systemic exposure during pregnancy for two probe medications: tacrolimus and oseltamivir.
Pharmacokinetic Modeling and Simulations of Human Anti-C1s Antibody (TNT009) in Normal Human Volunteers and Patients with Complement-mediated Disorders
Pharmacokinetic/Pharmacodynamic Analysis of Human Anti-C1s Antibody (TNT009) and Classical Complement Pathway (CP) Activity
Population Pharmacokinetic Modeling of Teduglutide to Support Dosing in Pediatric Patients with Short Bowel Syndrome
Certara Scientists Showcase PK/PD Modeling Advances at ASCPT Annual Meeting
PRINCETON, NJ – Mar. 13, 2017 – Certara today announced that its scientists will be highlighting pharmacokinetic (PK) and pharmacodynamic (PD) modeling advances during 19 sessions at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2017 Annual Meeting.
Changing the Game in Drug Development: A Selection from Certara’s Best of Blogs
A selection of short essays from our blog containing insights from our thought leaders on how modeling and simulation has impacted and is continuing to reshape our approach to drug development.
Accelerating the Pace of Generic Pharmaceutical Development
The formulation team at Impax Laboratories leveraged Certara’s IVIVC Toolkit for Phoenix WinNonlin to optimize generic formulations.